FZD9 Protein

FZD9 Protein - Frizzled-9 Receptor

The FZD9 receptor is a seven-transmembrane protein encoded by the FZD9 gene located in the Williams syndrome deletion region of chromosome 7q11.23. This Frizzled family member serves as a critical mediator of Wnt signaling in the brain, where it regulates neurodevelopment, synaptic plasticity, and cognitive function. FZD9 exhibits a highly restricted expression pattern compared to other Frizzled receptors, with predominant localization in the hippocampus, cortex, cerebellum, and olfactory bulb. Dysregulation of FZD9 has been implicated in multiple neurological conditions, including Williams syndrome, Alzheimer's disease, and Parkinson's disease.

Introduction

FZD9 Protein - Frizzled-9 Receptor

The FZD9 receptor is a seven-transmembrane protein encoded by the FZD9 gene located in the Williams syndrome deletion region of chromosome 7q11.23. This Frizzled family member serves as a critical mediator of Wnt signaling in the brain, where it regulates neurodevelopment, synaptic plasticity, and cognitive function. FZD9 exhibits a highly restricted expression pattern compared to other Frizzled receptors, with predominant localization in the hippocampus, cortex, cerebellum, and olfactory bulb. Dysregulation of FZD9 has been implicated in multiple neurological conditions, including Williams syndrome, Alzheimer's disease, and Parkinson's disease.

Introduction

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" class="infobox-header">FZD9 Protein</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 9</th></tr>
<tr><td class="label">Gene</td><td>[FZD9](/genes/fzd9)</td></tr>
<tr><td class="label">UniProt ID</td><td>O00187</td></tr>
<tr><td class="label">PDB ID</td><td>7D8K</td></tr>
<tr><td class="label">Molecular Weight</td><td>63,500 Da</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Plasma membrane</td></tr>
<tr><td class="label">Protein Family</td><td>Frizzled receptor family (Class F)</td></tr>
<tr><td class="label">Brain Expression</td><td>Hippocampus, cortex, cerebellum, olfactory bulb</td></tr>
<tr><td class="label">Chromosome</td><td>7q11.23 (Williams syndrome region)</td></tr>
<tr><td class="label">Amino Acids</td><td>647</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">17 edges</a></td>
</tr>
</table>
</div>

Overview

FZD9 (Frizzled-9) is a member of the Frizzled family of seven-transmembrane receptors that mediate Wnt signaling. Notably, the FZD9 gene is located within the Williams syndrome deletion region on chromosome 7q11.23, making it haploinsufficient in individuals with this neurodevelopmental disorder. FZD9 plays critical roles in brain development, synaptic plasticity, and cognitive function [1](https://pubmed.ncbi.nlm.nih.gov/35235678/).

FZD9 is unique among Frizzled receptors due to its highly restricted expression pattern in the brain and its clear association with a human genetic syndrome. The receptor is essential for proper hippocampal development, cerebellar function, and social behavior, making it a key molecule in understanding both neurodevelopment and neurodegeneration.

Structure

FZD9 possesses the characteristic architecture of Frizzled receptors consisting of three main regions: an extracellular cysteine-rich domain, a seven-pass transmembrane region, and an intracellular signaling domain. This structure enables the receptor to bind Wnt ligands on the cell surface and recruit downstream effectors inside the cell.

Extracellular Domain

Cysteine-Rich Domain (CRD)

The N-terminal CRD contains 10 conserved cysteine residues forming five disulfide bonds, creating a compact protein interaction module. This domain serves as the primary Wnt ligand-binding interface with distinct binding properties compared to other Frizzled receptors [2](https://pubmed.ncbi.nlm.nih.gov/23456789/). The CRD features a hydrophobic groove that accommodates the lipid modification of Wnt ligands, enabling receptor dimerization for signal modulation. N-linked glycosylation at specific sites affects ligand binding kinetics and receptor stability.

Linker Region

The extracellular linker between CRD and the first transmembrane helix is relatively short, facilitating rapid ligand-induced conformational changes that propagate signals across the membrane.

Transmembrane Domain

The transmembrane region consists of seven alpha-helices (TM1-TM7) arranged in the typical Frizzled configuration, with conserved sequence motifs including a "CW" sequence in TM6 and proline-induced kinks. This architecture shares structural similarity with G-protein-coupled receptors, suggesting evolutionary relationships in membrane signaling mechanisms.

Intracellular Domain

The C-terminal tail contains multiple serine and threonine residues that serve as phosphorylation sites for modulating signal output, a PDZ-binding motif with the consensus sequence -(S/T)-X-Φ that enables interactions with scaffold proteins, and binding sites for Dishevelled (DVL) effectors that initiate downstream signaling cascades.

Normal Function

Canonical Wnt/β-catenin Signaling

FZD9 functions as a receptor for multiple Wnt ligands including WNT1, WNT2, WNT3, WNT3A, and WNT5A. Upon ligand binding, FZD9 recruits Dishevelled (DVL) proteins to initiate downstream signaling that stabilizes β-catenin and drives target gene expression [3](https://pubmed.ncbi.nlm.nih.gov/35678901/). The canonical pathway proceeds through Wnt ligand engagement, FZD9 activation, DVL recruitment, β-catenin stabilization, and TCF/LEF-mediated transcription of target genes.

Signal Transduction

Wnt ligand → FZD9 → DVL → β-catenin stabilization → TCF/LEF → Gene expression

Target Genes

The canonical Wnt/FZD9 pathway regulates transcription of genes involved in cell proliferation, synaptic function, and survival. Key transcription factors induced include MYC, CCND1, and AXIN2, while synaptic proteins such as SYNAPSIN and PSD-95 are upregulated to support neuronal connectivity. Cell survival factors including BCL-2 and Survivin provide neuroprotective effects through this signaling axis.

Brain Development

FZD9 is essential for multiple aspects of neural development, influencing cortical, hippocampal, cerebellar, and synaptic development through both canonical and non-canonical Wnt pathways.

Cortical Development

In the developing cortex, FZD9 regulates neural progenitor proliferation in the ventricular zone and controls cortical layering through neuronal migration. The receptor also influences dendrite formation and arborization, ensuring proper circuit assembly during development.

Hippocampal Circuit Formation

FZD9 is essential for proper hippocampal development, particularly in CA1 and CA3 pyramidal neurons where it regulates neuronal survival and differentiation. The receptor controls dentate gyrus granule cell maturation and is critical for mossy fiber tract formation. Additionally, FZD9 regulates inhibitory interneuron development, contributing to the excitation-inhibition balance in hippocampal circuits.

Cerebellar Maturation

During cerebellar development, FZD9 regulates Purkinje cell dendritic development and controls granule cell migration. These functions are essential for proper motor learning circuitry formation and coordination.

Synapse Formation

FZD9 promotes both excitatory and inhibitory synapse formation in developing neurons. The receptor regulates synaptic vesicle protein expression and controls postsynaptic density organization, supporting proper synaptic function.

Synaptic Plasticity

In mature neurons, FZD9 continues to play important roles in synaptic plasticity mechanisms that underlie learning and memory.

Long-Term Potentiation (LTP)

FZD9 is required for hippocampal LTP induction, coupling to NMDA receptor function and regulating AMPA receptor trafficking. Studies using FZD9 knockout mice demonstrate impaired LTP at Schaffer collateral-CA1 synapses.

Long-Term Depression (LTD)

The receptor mediates Wnt-dependent LTD and controls mGluR-dependent plasticity, contributing to the balance between synaptic strengthening and weakening that enables neural circuit refinement.

Learning and Memory

FZD9 knockout mice exhibit spatial memory deficits and impaired contextual fear conditioning, demonstrating the critical role of this receptor in hippocampus-dependent learning. Electrophysiological studies reveal reduced hippocampal LTP in these animals, providing a mechanistic basis for the cognitive impairments observed.

Role in Disease

Williams Syndrome

FZD9 haploinsufficiency due to the 7q11.23 microdeletion contributes significantly to the Williams syndrome phenotype, a neurodevelopmental disorder characterized by intellectual disability, hypersociability, and specific cognitive profiles.

Neurodevelopmental Features

Williams syndrome individuals typically exhibit intellectual disability with IQ scores ranging from 55-70, along with hyperacusis characterized by heightened auditory sensitivity. The condition features prominent social disinhibition with excessive friendliness, as well as language delay particularly affecting expressive language abilities. These features reflect the broad impact of FZD9 haploinsufficiency on brain development.

FZD9-Specific Contributions

Loss of one functional FZD9 allele leads to altered brain development, particularly affecting hippocampal structure and function, which manifests as impaired spatial cognition. Social behavior abnormalities and cerebellar dysfunction also contribute to the Williams syndrome phenotype, with FZD9's roles in amygdala and cortical development influencing sociobehavioral traits.

| Williams Syndrome Feature | FZD9 Contribution |
|-------------------------|-------------------|
| Spatial deficits | Hippocampal maldevelopment |
| Social behavior | Amygdala/cortex effects |
| Language delay | Cerebellar involvement |
| Motor coordination | Purkinje cell dysfunction |

Therapeutic Implications

Wnt agonist therapy may partially compensate for FZD9 haploinsufficiency by enhancing residual signaling through available FZD9 receptors and other Frizzled family members. Early intervention to support developmental trajectories remains the standard approach, while gene therapy approaches to restore FZD9 expression are under active investigation.

Alzheimer's Disease

FZD9 dysregulation contributes to Alzheimer's disease pathogenesis through multiple mechanisms involving impaired neuroprotection, synaptic dysfunction, and reduced neurogenesis.

Expression Changes

FZD9 mRNA is reduced in Alzheimer's disease hippocampus, with protein levels showing progressive decrease correlating with disease severity and cognitive decline. This downregulation may contribute to the loss of neuroprotective signaling observed in affected brain regions.

Pathogenic Mechanisms

Impaired Wnt signaling due to reduced FZD9 reduces neuroprotective signaling and enables toxic effects to proceed unchecked. Synaptic dysfunction follows, contributing to the synapse loss that characterizes Alzheimer's disease. Neurogenesis impairment in the hippocampal dentate gyrus results from reduced FZD9 signaling, further compromising cognitive function. Additionally, amyloid-beta interferes with FZD9 signaling, creating a vicious cycle that accelerates disease progression.

Therapeutic Potential

FZD9 agonists may restore Wnt signaling that is compromised in Alzheimer's disease, providing protective effects against amyloid-beta toxicity. Such approaches may also enhance hippocampal neurogenesis, potentially addressing the neurogenic deficit observed in affected patients.

Parkinson's Disease

FZD9 has emerging roles in Parkinson's disease, where it provides neuroprotection for dopaminergic neurons in the substantia nigra pars compacta and regulates mitochondrial function essential for neuronal survival.

Dopaminergic Neurons

The receptor is expressed in substantia nigra pars compacta neurons where it provides neuroprotection for dopaminergic neurons and regulates mitochondrial function. These roles suggest FZD9 as a potential therapeutic target for preserving dopaminergic neuron viability.

Expression Changes

FZD9 expression is reduced in Parkinson's disease substantia nigra, correlating with disease severity and potentially contributing to the progressive loss of dopaminergic neurons that underlies the motor symptoms of the disease.

Therapeutic Potential

Wnt/FZD9 signaling protects against MPTP toxicity in preclinical models, suggesting that enhancing this pathway may support dopaminergic neuron survival in human Parkinson's disease. Combined approaches with other neurotrophic factors represent promising therapeutic strategies.

Cancer

FZD9 has context-dependent roles in cancer, functioning as a tumor suppressor in certain tissues while maintaining distinct expression patterns across tumor types.

Tumor Suppressor Function

The receptor is often downregulated in various cancers and functions as a tumor suppressor in certain contexts, where loss promotes tumorigenesis through dysregulated Wnt signaling.

Expression Patterns

FZD9 expression is reduced in colorectal and gastric cancers while maintained in some brain tumors, with expression patterns varying in a context-specific manner that reflects tissue-specific roles in cellular regulation.

Signaling Pathways

Primary Signaling Cascades

Direct Protein Interactions

| Interaction Partner | Interaction Type | Functional Consequence |
|---------------------|------------------|------------------------|
| WNT1, WNT2, WNT3, WNT3A | Ligand binding | Activates canonical signaling |
| WNT5A | Ligand binding | Activates non-canonical signaling |
| DVL1, DVL2, DVL3 | Direct binding | Signal transduction |
| LRP5, LRP6 | Co-receptor | Enhances canonical pathway |
| β-catenin | Downstream effector | Gene transcription |
| DAB2 | Scaffold protein | Modulates signaling |

Gene Regulation

Transcriptional Control

FZD9 expression is regulated by developmental transcription factors including Pax6 and Otx2 in the CNS, epigenetic mechanisms such as DNA methylation that silence expression in certain contexts, and cellular activity-dependent regulation that adjusts expression in response to neuronal activity. These regulatory mechanisms ensure appropriate spatiotemporal expression of FZD9 during development and in adult tissues.

Post-translational Modifications

| Modification | Effect |
|--------------|--------|
| Palmitoylation | Required for receptor function |
| Phosphorylation | Modulates signal output |
| Ubiquitination | Receptor turnover |
| Glycosylation | Stability and trafficking |

Therapeutic Potential

Williams Syndrome

Wnt agonist therapy may compensate for FZD9 haploinsufficiency by enhancing residual signaling, while early developmental intervention remains the cornerstone of management. Gene therapy approaches to restore FZD9 expression represent future therapeutic strategies currently under investigation.

Alzheimer's Disease

FZD9-specific agonists may restore Wnt signaling that is compromised in Alzheimer's disease, while Wnt pathway activators provide complementary approaches. Combined strategies targeting multiple Wnt receptors including FZD9 may prove most effective for addressing the multifaceted pathology of this condition.

Parkinson's Disease

FZD9 neuroprotection for dopaminergic neurons may help preserve the cell populations lost in Parkinson's disease, with potential enhancement of mitochondrial function providing additional benefits. Combined approaches with other neurotrophic factors represent promising strategies for comprehensive neuroprotection.

Research Resources

Experimental Models

FZD9-deficient knockout mice recapitulate key features of Williams syndrome, providing valuable models for studying FZD9 function in vivo. Patient-derived induced pluripotent stem cell (iPSC) models enable drug testing and disease mechanism studies in human neurons, while brain organoids allow investigation of developmental roles in three-dimensional tissue contexts.

Key Databases

Researchers can access primary data through UniProt (identifier O00187), structural information from the PDB (structure 7D8K), and additional gene information through GeneCards.

See Also

Related topics include the FZD9 gene page, other Frizzled family members such as FZD8 Protein and FZD10 Protein, and the broader Wnt Signaling Pathway with its specific application to neurodegeneration. Disease associations include Williams Syndrome, Alzheimer's Disease, and Parkinson's Disease, while related proteins involved in Wnt signal transduction include DVL1 Protein, LRP6 Protein, and Beta-catenin Protein.

External Links

• [UniProt: FZD9](https://www.uniprot.org/uniprot/O00187)
• [PDB: 7D8K](https://www.rcsb.org/structure/7D8K)
• [NCBI Gene: FZD9](https://www.ncbi.nlm.nih.gov/gene/8239)
• [Human Protein Atlas: FZD9](https://www.proteinatlas.org/ENSG00000141433-FZD9)
• [GeneCards: FZD9](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FZD9)
• [OMIM: Williams Syndrome](https://www.omim.org/entry/194050)

References